The US Federal Trade Commission (FTC) has approved a final order settling charges that healthcare company UnitedHealth’s $4.3 billion acquisition of DaVita Medical would harm competition.
Gilead Sciences, the maker of HIV drug Truvada, has asked the US Patent and Trademark Office to review patents granted to the government covering preventative use of the drug.
A leaked UK government report reveals that a no deal Brexit may result in shortages of medicines and other pharmaceutical products.
Bayer has agreed to sell its animal health business to US-based Elanco Animal Health for $7.6 billion, as part of its strategic plan to focus on its core life sciences businesses.
Amneal and three other generic makers have agreed to pay $1.54 million to settle a class-action lawsuit, which alleged the companies engaged in an unlawful scheme to maintain their monopoly over an Alzheimer’s drug.
The US and Europe have reached the same conclusion in more than 90% of marketing authorisation decisions for new medicines, according to a report from the European Medicines Agency.
Several pharma bodies have signed non-disclosure agreements which prevent them from disclosing the UK government’s plans for a no-deal Brexit.
The US Court of Appeals for the Federal Circuit yesterday, August 15, blocked Actavis’s attempt to market a generic version of Nalpropion Pharmaceuticals’ weight-loss drug Contrave.
Sanofi secured a win at the US Court of Appeals for the Federal Circuit yesterday, August 14, after the appeals court concluded a lower court lacked authority to invalidate claims of a patent covering a prostate cancer drug.
Drugmaker Aspen has offered to pay the UK’s National Health System £8 million to resolve competition concerns.